Related Experiment Video
Updated: Aug 3, 2025

08:43
Application of Granger Causality Analysis of the Directed Functional Connection in Alzheimer's Disease and Mild Cognitive Impairment
Published on: August 7, 2017
8.0K
GCCN: Graph Capsule Convolutional Network for Progressive Mild Cognitive Impairment Prediction and Pathogenesis
IEEE Journal of Biomedical and Health Informatics
|April 8, 2023
Summary
A new Graph Capsule Convolutional Network (GCCN) predicts mild cognitive impairment to dementia progression by identifying pathogenic factors. This method reveals key disease-related information flows for better understanding and potential intervention.
Area of Science:
- Neuroscience
- Computational Biology
- Artificial Intelligence
Background:
- Mild cognitive impairment (MCI) is a precursor to dementia, necessitating accurate prediction and understanding of its pathogenesis.
- Identifying key pathogenic factors and their interactions is crucial for developing effective interventions.
- Current methods may not fully capture the complex, heterogeneous nature of disease progression.
Purpose of the Study:
- To propose a novel Graph Capsule Convolutional Network (GCCN) for predicting MCI to dementia progression.
- To identify the underlying pathogenesis and key risk factors involved in disease development.
- To leverage heterogeneous pathogenic information for a more comprehensive disease model.
Main Methods:
- Constructed heterogeneous pathogenic information association graphs using risk genes and brain regions as nodes.
- Developed graph capsules by projecting information into disentangled latent components representing format and intensity.
- Employed GCCN to model information flow among pathogenic factors and identify disease-driving pathways via dynamic routing.
Main Results:
- GCCN demonstrated significant advancements over existing methods on public datasets.
- The identified pathogenic factors were evidential and strongly correlated with progressive MCI.
- The dynamic routing mechanism successfully captured discriminative pathogenic information flows.
Conclusions:
- GCCN offers a powerful new approach for predicting MCI to dementia progression.
- The method effectively identifies key pathogenic factors and elucidates disease mechanisms.
- This work provides a foundation for developing targeted diagnostic and therapeutic strategies.
Related Concept Videos
Alzheimer's Disease: Overview
555
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
555
Prosopagnosia
212
Prosopagnosia, also known as face blindness, is the inability to recognize faces. In severe cases, individuals with prosopagnosia may not recognize close family members, including parents and spouses, by their faces. For instance, someone with prosopagnosia might walk past their child in a crowd, only realizing their mistake upon noticing their child's distinctive backpack or favorite jacket. Prosopagnosia specifically impairs facial recognition, while the recognition of other objects or...
212
Brain Imaging
270
Brain imaging technologies provide critical insights into both the structure and function of the human brain, enabling medical professionals and researchers to diagnose, study, and treat neurological disorders or psychiatric disorders more effectively.
These technologies include computerized axial tomography (CAT or CT scans), positron-emission tomography (PET scans), magnetic resonance imaging (MRI), functional magnetic resonance imaging (fMRI), and Transcranial Magnetic...
These technologies include computerized axial tomography (CAT or CT scans), positron-emission tomography (PET scans), magnetic resonance imaging (MRI), functional magnetic resonance imaging (fMRI), and Transcranial Magnetic...
270
Alzheimer's Disease: Treatment
232
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
232

